We are proud to announce that on November 10, 2022, we successfully submitted an application to the URPL for market authorization of the medicinal product TraMag® Plus in Poland. At the same time on October 25 we received the expected response to our pre-IND submitted to the FDA in early 2022. These next milestones will allow us to further develop our plans for TraMag® Plus in EU and US.
Thanks to our Partners from SciencePharma, MEDICOFARMA S.A. Contract Manufacturer and Premier Consulting
